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We investigated the phenotypic expression of factor H
mutations in two patients with atypical hemolytic uremic
syndrome (HUS). Factor H in serum was assayed by rocket
immunoelectrophoresis, immunoblotting, and double
immunodiffusion and in tissue by immunohistochemistry.
Functional activity was analyzed by hemolysis of sheep
erythrocytes and binding to endothelial cells. A homozygous
mutation in complement control protein (CCP) domain 10 of
factor H was identified in an adult man who first developed
membranoproliferative glomerulonephritis and later HUS. C3
levels were very low. The patient had undetectable factor H
levels in serum and a weak factor H 150 kDa band. Double
immunodiffusion showed partial antigenic identity with
factor H in normal serum owing to the presence of factor
H-like protein 1. Strong specific labeling for factor H was
detected in glomerular endothelium, mesangium and in
glomerular and tubular epithelium as well as in bone marrow
cells. A heterozygous mutation in CCP 20 of factor H was
found in a girl with HUS. C3 levels were moderately
decreased at onset. Factor H levels were normal and a normal
150 kDa band was present. Double immunodiffusion showed
antigenic identity with normal factor H. Factor H labeling was
minimal in the renal cortex. Factor H dysfunction was
demonstrated by increased sheep erythrocyte hemolysis and
decreased binding to endothelial cells. In summary, two
different factor H mutations associated with HUS were
examined: in one, factor H accumulated in cells, and in the
other, membrane binding was reduced.
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Factor H is the main regulatory protein of the alternative
pathway of complement and is composed of 20 complement
control protein (CCP) domains.1 Factor H inhibits formation
of the C3bBb convertase by preventing the binding of factor
B to C3b, and accelerates the decay of this convertase.
Furthermore, it serves as a cofactor for factor I in the
degradation of C3b to iC3b.2 iC3b cannot participate in the
formation of C3 convertase.2 Factor H circulates in human
plasma as a 150 kDa protein. In addition, factor H-like
protein 1 (FHL-1), which is composed of CCPs 1–7, circulates
as a 42 kDa protein derived by alternative splicing of the
factor H transcript. Both proteins have complement
regulatory functions.3
Factor H discriminates between host cells and foreign cells
by binding to glycosaminoglycans on the surface of host cells
and thus protects host cells and tissues from complement-
mediated cell lysis.4 Factor H is primarily synthesized in
hepatocytes but also expressed in monocytes, fibroblasts,
mesangial cells, endothelial cells, and neuronal cells (reviewed
by Friese et al.3), and is stored in the a granules of platelets.5
Factor H mutations have been identified in a subset of
patients with atypical hemolytic uremic syndrome (HUS)6–13
and in membranoproliferative glomerulonephritis (MPGN)
types I, II, and III.13–16 HUS is characterized by microangio-
pathic hemolytic anemia, thrombocytopenia, and acute renal
failure,17 and MPGN is characterized by nephritic–nephrotic
syndrome usually occurring in conjunction with activation of
the alternative complement pathway.18 Factor H mutations in
patients with MPGN are homozygous,19 whereas mutations
in HUS are more often heterozygous.6–10 Most mutations in
HUS have been localized to CCP 207 at the C terminus of the
protein, a region involved in C3b binding as well as in
heparin binding and host recognition.20
The mechanisms by which factor H mutations may lead to
HUS and MPGN are not fully understood. Premature stop
codons interrupt transcription and thus abolish factor H or
FHL-1 synthesis.7,10,21 In the porcine MPGN type II model, a
mutation in CCP 20 affected factor H secretion from
hepatocytes.22 Likewise, a patient with hypocomplementemic
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glomerulonephritis and factor H deficiency based on a
compound heterozygous mutation involving conserved
cysteine residues in CCPs 9 and 16 was found to have
blocked cellular secretion of factor H, but a normal level of
FHL-1.23 Amino-acid substitutions in CCP 20 have been
shown, in an in vitro model, to affect ligand binding to the
surface of endothelial cells.24 Mutations may thus lead to
defective host recognition, allowing complement to be
activated on host endothelial cells leading to vascular
injury.24,25 A recent study demonstrated that, in atypical
HUS, mutations in factor H led to defective regulation of
complement activation on the surface of sheep erythro-
cytes.26
The aim of this study was to correlate factor H mutations
in two patients, with MPGN and HUS, with protein
expression in blood and tissue and dysfunction affecting
binding to endothelial cells as well as cellular protection from
complement activation.
RESULTS
Mutation detection in the factor H gene
Genomic DNA from the two patients and from the parents of
patient 2 were screened for mutations in the factor H gene by
polymerase chain reaction (PCR) and sequencing of 23 exons
excluding exon 10 (encoding the C terminus of FHL-1
protein). In patient 1 a novel homozygous mutation in exon
13, corresponding to CCP 10, was found at C1934A (Figure
1a), leading to replacement of proline by threonine (P621T),
nucleotide and amino acid positions as per Richards et al.6
Sequencing of the patient’s entire factor H gene indicated
homozygosity. The patient’s parents were cousins. Single-
strand conformational polymorphism analysis of exon 13
from 30 controls was carried out showing that the patient’s
sample differed from the normal pattern (Figure 1b).
In patient 2 a heterozygous mutation in exon 23,
corresponding to CCP 20, was found at G3665A (Figure
1c), leading to replacement of glutamic acid by lysine
(E1198K). No mutations were found in the other allele. This
appears to be a de novo mutation, as no mutations were
found in DNA from the patient’s parents (non-paternity
excluded). The mutation was confirmed by restriction
enzyme cleavage, as it creates a new MseI site (Figure 1d).
Sequencing of cDNA confirmed that the patient was
heterozygous for the E1198K mutation and that both alleles
were expressed (Figure 1e).
Phenotypic expression of factor H in serum
Patient 1 had undetectable levels of factor H in serum, as
assayed by rocket immunoelectrophoresis (Figure 2a). A very
weak band was detected at 150 kDa by immunoblotting, but a
normal 42 kDa band indicated the presence of FHL-1 (Figure
2b). Double immunodiffusion experiments gave a pattern of
partial identity with factor H in normal serum (Figure 2c),
evidently owing to the presence of FHL-1.
Patient 2 had normal levels of factor H in serum (Figure
2d) and normal 150 and 42 kDa bands (Figure 2e). Double
immunodiffusion experiments gave a reaction of antigenic
identity with factor H antigen in normal serum (Figure 2f).
Phenotypic expression of factor H and C3 in the renal cortex
Immunohistochemistry experiments exhibited factor H
labeling in normal renal cortex, primarily in glomerular
capillary endothelium, as well as in mesangium and
glomerular epithelium (Figure 3a). Weaker labeling was also
found in tubular epithelial cells. There were no differences
between renal cortex from adult and pediatric controls. A
similar pattern albeit stronger was found in the glomeruli of
patient 1 (Figure 3b), indicating cellular accumulation of
factor H. Weak staining was noted in few tubular cells (data
not shown). As the patient expressed FHL-1, but not factor
H, in the circulation, the biopsy was also labeled with the
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Figure 1 | Factor H mutations in two patients. (a) Patient 1: A
homozygous mutation in exon 13, C1934A, is compared to the
wild-type exon 13. (b) Single-strand conformational polymorphism
analysis of exon 13 (CCP 10) in patient 1 (lane 1) and 10 healthy
controls (lanes 2–11), showing only one band in the patient. The
normal pattern of two bands was obtained for an additional 20 DNA
samples from healthy controls (not shown). (c) Patient 2: A
heterozygous missense mutation in exon 23, G3665A, compared to
the wild-type exon. (d) Digestion products of MseI from a PCR
product of exon 23, showing fragments of 190, 141, 125, 81, and
49 bp. Two extra bands at 141 and 49 bp were detected only in
patient 2 (lane 1) and originate from cleavage at a new MseI site
(T0TAA at position 3663–3664) in one of the alleles (lanes 2–8 show
the normal pattern in seven controls, of a total of 15 controls
included in the study). (e) To study expression of both normal and
mutated factor H in patient 2, we designed primers to amplify part of
CCP 19 and all of CCP 20 as well as part of the 30 untranslated region
from cDNA. Sequencing of the factor H transcript from patient 2
showed expression of both normal and mutated alleles.
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VIG8 antibody specific for CCPs 19–20 (which does not
crossreact with FHL-1). Similar staining was found (data not
shown), indicating that the staining was specific for factor H.
In the renal cortex of patient 2, minimal staining was found
in few glomerular capillaries and mesangial cells as well as in
glomerular epithelium (Figure 3c).
C3 was not detectable in the normal renal cortex (Figure
3d). C3 staining was found in the renal cortex of both
patients (Figure 3e and f). Specific C3 staining was noted in
glomerular capillaries. In patient 1 labeling corresponded
with areas of positive labeling for factor H.
Specificity of the assay was demonstrated by preincuba-
tion of anti-factor H with factor H. When the preincubated
antibody was incubated with renal sections, no labeling
was detected (Figure 3g). Similarly, there was no staining of
renal cortex incubated with the control antibody (data not
shown). Positive staining of hepatocytes for factor H was
found in liver sections (Figure 3h), but not in colon sections
(Figure 3i).
Phenotypic expression of factor H in bone marrow
Immunohistochemistry of the normal bone marrow showed
factor H staining in monocytes, megakaryocytes as well as in
other cells (Figure 4a). Bone marrow from patient 1 showed a
similar cellular distribution of factor H with labeling in
monocytes (Figure 4b) and megakaryocytes (Figure 4c).
Antibody specificity was confirmed as for renal biopsies.
Factor H function
Hemolysis of sheep erythrocytes. Serum from patient 2 and
controls was assayed with regard to the ability of factor H to
protect sheep erythrocytes from lysis. Addition of normal
serum to sheep erythrocytes gave 1% (median, range 0–4.5%)
hemolysis in the adult sera (n¼ 16) and 0% (range 0–1.7%)
hemolysis in the pediatric sera (n¼ 12). Addition of serum
from patient 2 resulted in 31.2% hemolysis (range 29.5–33%,
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Figure 2 | Factor H levels, size, and antigenicity. (a) Standard
dilutions of pooled normal sera (25–200% of the normal serum level;
lanes 1–4) were compared by rocket immunoelectrophoresis with
undiluted serum from patient 1 (lane 5) demonstrating factor H
deficiency. (b) Immunoblot analysis of factor H using polyclonal
anti-factor H antibody. Serum from a normal individual (lane 1) was
compared with patient 1 (lane 2) showing that the patient has a very
weak band at 150 kDa owing to a very low level of factor H and a
normal band at 42 kDa representing FHL-1 protein (lane 2). (c) Double
immunodiffusion according to Ouchterlony. Serum samples and
polyclonal goat anti-human factor H antibody were allowed to
diffuse for 48 h at room temperature in agarose. Immunoprecipitates
were stained with Coomassie brilliant blue (Sigma-Aldrich, St Louis,
MO). Serum from patient 1 (P) diffused against polyclonal anti-factor
H antibody in comparison with control plasma (C). The precipitate
formed with the patient’s serum is ascribed to interaction between
FHL-1 and the antibody. (d) Factor H level in the serum of patient 2
analyzed by rocket immunoelectrophoresis indicating a normal level
(lane 5) in comparison to standard dilutions of pooled sera (lanes
1–4). (e) Immunoblot analysis of factor H in serum from a normal
individual (lane 1) compared with patient 2 (lane 2) showing that the
patient has a normal band. Samples shown in (b) and (e) were
analyzed on the same gel and the normal serum control is therefore
the same. (f) Double immunodiffusion. Serum from patient 2 (P)
diffused against polyclonal anti-factor H antibody, in comparison
with control plasma (C) showing a reaction pattern of antigen
identity.
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Figure 3 | Immunohistochemistry of renal cortex labeled with
anti-factor H and anti-C3 antibodies. (a) Normal renal cortex from
an adult showing prominent brown factor H labeling of glomerular
capillaries (-), mesangial cells (c), and epithelium ( ) as well as
tubular epithelial cells ( ). (b) Renal cortical biopsy from patient 1
showing strong factor H labeling following the same cellular
distribution in glomerular capillaries, mesangial cells, and epithelium
as the normal kidney. (c) Renal cortical biopsy from patient 2 showing
minimal factor H labeling in few glomerular capillaries, mesangial
cells as well as in glomerular epithelium. (d) C3 staining was not
detectable in the normal renal cortex. The renal cortical biopsies from
patient 1 (e) and patient 2 (f) showed C3 labeling in glomerular
capillaries (arrows as per (a)). (g) Preincubation of the anti-factor H
antibody with factor H (20 mg/ml) for 1 h at 371C abolished labeling of
the normal renal cortex indicating specificity. (h) Liver sections were
labeled with the anti-factor H antibody as a positive control showing
factor H labeling in hepatocytes (see arrow). (i) Colon sections were
tested as a possible negative control, and demonstrated lack of factor
H labeling.
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three experiments). Hemolysis was abolished when purified
factor H was added. The results indicate that patient factor H
has a decreased ability to protect erythrocytes, thus enabling
complement-mediated hemolysis to occur.
Binding of factor H to endothelial cells detected by immuno-
fluorescence and flow cytometry. Factor H in serum bound to
human umbilical vein endothelial cells (HUVECs) as
detected by immunofluorescence (Figure 5). Minimal bind-
ing was detected using the serum from patient 1 (Figure 5a),
moderate binding was detected using serum from patient 2
(Figure 5b), and strong fluorescence was detected with
normal serum (Figure 5c).
Similarly, factor H binding to endothelial cells was
detected by flow cytometry. Purified factor H bound to
21% of the cell population (range 15–27% binding). Factor H
from normal serum bound to 17.5% of cells (range 8–27%
binding; Figure 5d). Very low binding was detected when
serum from patient 1 was incubated with the cells (0.74%
binding, range 0.59–0.89%; Figure 5d). Decreased binding
compared to normal was found when serum from patient 2
was incubated with the cells (6.9% binding, range 5.9–7.8%;
Figure 5d). Taken together with the hemolysis assay, the
results indicate that factor H from patient 2, although present
in normal quantities, is functionally impaired with regard to
binding and host recognition properties.
DISCUSSION
This study correlates the genotypic and phenotypic expres-
sion of two novel factor H mutations with different
presentations of atypical HUS. Patient 1 presented as an
adult with MPGN and later developed atypical HUS. He did
not have detectable levels of factor H in the circulation, but
was found to have an intracellular accumulation of the
protein, as shown in kidney and bone marrow biopsies.
Patient 2 presented as a child and had normal factor H levels.
Minimal factor H staining was detected in the renal cortex.
The patient’s factor H was dysfunctional in that it did not
protect sheep erythrocytes from complement-mediated
hemolysis and exhibited decreased binding to endothelial
cells. A recent study demonstrated that HUS-related factor
H mutants exhibited reduced affinity to endothelial cells.24
The current study demonstrates this using patient serum.
Both patients had complement activation as indicated by
decreased concentrations of circulating C3 (in patient 2, only
initially) and by C3 deposition in glomeruli. We suggest that
factor H deficiency or the presence of dysfunctional factor H
could potentially expose endothelial cells to complement
activation via the alternative pathway resulting in endothelial
cell injury.
Factor H expression in tissues has not been previously
studied in atypical HUS. Studies in normal renal tissue have
shown that the protein is expressed in blood vessels of the
renal cortex as well as in mesangial cells in adult kidneys and
in the tubuli of fetal kidneys.27 Furthermore, mRNA
expression indicated that the protein is synthesized in the
kidney27,28 and is specifically found in glomerular and
tubular fractions.29 In this study, we detected factor H in
glomerular endothelial and epithelial cells as well as in
mesangial and tubular cells. In hepatocytes factor H labeling
appeared to be intracellular. In the renal cells we could not
distinguish between intracellular and cell-surface labeling. As
factor H is known to protect cell surfaces from complement
activation,4 we assume that some of the factor H staining
seen in the renal cortex, particularly on capillary endothe-
lium, is located on cell surfaces. In patient 1 we show
expression and accumulation of factor H in glomerular
capillary endothelium, mesangial cells, and tubular epithe-
lium. As the protein is not found in the circulation, and as
others have shown both mRNA expression and protein
synthesis in these cells,28,29 our findings suggest that the
protein is synthesized in these cells but not secreted.
Similarly, factor H accumulated in monocytes and mega-
karyocytes in bone marrow. Monocytic cell lines have also
been shown to contain mRNA for factor H,30 indicating, in a
a b c
Figure 4 | Immunohistochemistry of bone marrow labeled with
anti-factor H antibody. (a) Normal bone marrow showing promi-
nent brown staining of monocytes ( ) and megakaryocytes ( ). Bone
marrow from patient 1 showed prominent staining in (b) monocytes
and (c) megakaryocytes following the same pattern of cellular
distribution as for normal bone marrow.
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Figure 5 | Factor H binding to endothelial cells detected by
immunoflourescence and flow cytometry. (a–c) Immunofluores-
cence for detection of serum factor H bound to HUVEC surfaces,
demonstrating very low binding of factor H from patient 1 (a),
moderate binding of factor H from patient 2 (b), and normal binding
with stronger immunfluorescent labeling of factor H from normal
serum (c). (d) One representative flow cytometry experiment showing
binding of factor H to HUVECs. Serum from patient 1 exhibited 0.59%
factor H binding (thin line), from patient 2, 7.8% binding (gray line),
and normal serum 27% binding (thick line). Percentages were
calculated after subtraction of the background fluorescence.
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corresponding fashion, that factor H is produced by these
cells, but not released.
Platelets may contain proteins synthesized in megakaryo-
cytes or may internalize external proteins for storage.31 The
finding that megakaryocytes contain factor H is novel and
indicates that factor H may be produced by these cells. In
addition to its presence in megakaryocytes, we have recently
shown that factor H binds to platelets.32 Although the
biological consequences of this interaction are not fully
understood, it may indicate that factor H regulates comple-
ment activation on the platelet surface.
In patient 2 very weak staining of factor H was detected in
the renal cortex. This could be explained by decreased cellular
synthesis or diminished binding to cell surfaces. Another
possibility could be impaired antigenicity of factor H. Our
results indicate that antigenicity was not altered, as the same
polyclonal antibody was fully reactive with the patient’s
factor H in serum. Decreased renal synthesis of factor H
cannot be ruled out, especially as factor H is mostly produced
in the liver;3 however, as the patient had normal levels of
factor H in serum, this possibility appeared less likely. For
this reason, we tested the ability of the patient’s factor H to
bind to endothelium, and found binding to be decreased
compared to normal factor H. We conclude that the weak
factor H staining of the renal cortex in this patient is due to
reduced binding of the patient’s factor H to cell surfaces.
The mutation in patient 2 was a de novo mutation in the
C-terminal region of factor H. De novo mutations are rare
but have been previously associated with HUS.12 Most of the
mutations in HUS patients are located in the C terminus of
the protein.7,12,33,34 This region is important for host
recognition35 via heparin binding sites36 and for C3b/C3d
binding.37 Mutations in this region support normal cofactor
activity regarding C3b breakdown33 but give rise to decreased
binding to surface-fixed C3b33,37 and C3d as well as to
heparin.24 A mutation in this region will affect the capacity of
factor H to discriminate between host and foreign cells38 and
also promote complement activation. Our study demon-
strates that the mutation generates dysfunctional factor H,
which could not protect sheep erythrocytes from hemolysis.
This specific mutation has not been previously described,
although another mutation in the same amino-acid position
has been described in a patient with atypical HUS
(E1198A).11 This amino acid is located near the heparin
binding residues in CCP 2036,37 and could thus affect binding
to cell membranes and host recognition.
A mutation in CCP 10, which we have found in patient 1,
has not been described previously. However, factor H
deficiency has been described in patients with MPGN13,15,16
as well as meningococcal disease,39 and factor H mutations in
MPGN are not specifically located to one region of the
protein. Factor H deficiency has been associated with MPGN
types I,13 II,15,16 and III.16 Although patients with both
MPGN and atypical HUS have been described,40–42 the
combination of these conditions in patient 1 is unusual. The
mutation located in CCP 10 would enable patient 1 to
synthesize normal CCPs 1–7, that is, FHL-1, as shown by a
normal band at 42 kDa. A patient with hypocomplementemic
glomerulonephritis and factor H deficiency but normal FHL-1
has been described previously.23 In vitro experiments have
shown that FHL-1 functions as a cofactor of factor I in the
cleavage of C3b and that it possesses decay-acceleration
activity that dissociates the C3bBb complex.43,44 The latter
function appears less efficient for FHL-1 than for factor H.44
The description of our patient and a previous patient with
complement consumption and normal serum FHL-123
indicates that FHL-1 does not play an important role in
complement regulation in the circulation.
This study compares two abnormal genotypes and tissue
phenotypes of factor H mutations: in one, factor H
accumulated inside cells, and in the other, factor H binding
to endothelium was defective. We suggest that these mutations
will lead to dysfunctional host recognition and uninhibited
complement activation on the surface of endothelial cells,
which will contribute to the pathogenesis of HUS.
MATERIALS AND METHODS
Subjects
Patient 1, deceased at 51 years of age, was treated at the Department
of Renal Medicine, Huddinge University Hospital, Stockholm. The
patient had hepatitis B during his youth and was admitted at the age
of 48 years, in August 2001, with nephrotic syndrome and decreased
renal function (glomerular filtration rate 46 ml/min/1.73 m2).
Complement analysis was carried out, according to accredited
hospital routines, as presented in Table 1. C3 levels were persistently
o0.10 g/l in this patient. Renal biopsy, examined by light,
immunofluorescent, and electron microscopy showed MPGN with
duplication of the glomerular basement membrane. In the
glomerular capillaries endothelial cell swelling and a few thrombi
were noted. Global sclerosis was found in 13 of 21 glomeruli.
Deposits of C3 were demonstrated in the capillary basement
membrane and in the mesangium. Electron microscopy showed
deposits in the subendothelium (MPGN type I). In May 2002, the
patient experienced a temporary deterioration of liver function, and
2 months later, developed nonimmune hemolytic anemia (hemo-
globin 70 g/l; reference area 130–165 g/l), reticulocytosis (201 109/l;
reference area 30–140 109/l), low haptoglobin (o0.1 g/l; reference
area 0.24–1.9 g/l), thrombocytopenia (85 109/l; reference value
150–400 109/l), increased lactate dehydrogenase (18.6 mkat/l;
reference areao6.5 mkat/l), and progressive renal failure (creatinine
increased from 292 to 521 mmol/l within 6 days; reference area
Table 1 | Complement profiles for patients 1 and 2
Complement profiles Range Patient 1 Patient 2
C3 (g/l) 0.67–1.29 o0.10 1.16a
Factor B (%) 59–154 23 125
C5 (%) 72–171 57 169
Properdin (%) 54–157 24 163
Factor I (%) 60–152 140 175
Factor H (%) 69–154 o3 105
C4 (g/l) 0.12–0.33 0.47 0.46
C1q (%) 150–270 295 151
C3d (mg/l) o7 32 Not available
aThis patient had low C3 at the debut of HUS (0.56 g/l), which normalized later in the
course of disease.
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60–104 mmol/l) followed by malignant hypertension. A bone marrow
biopsy was carried out because the diagnosis was initially unclear.
This showed a hypercellular marrow with active erythropoiesis due
to hemolysis. A diagnosis of atypical HUS was made and the patient
was treated with plasma exchange and corticosteroids followed by
hemodialysis. A blood sample was taken before the start of plasma
exchange and several months after its termination. The patient did
not develop further clinical signs of HUS, but succumbed in 2004 to
a cerebrovascular accident. The samples were taken with the
informed consent of the patient and with the approval of the Ethics
Committees of Lund and Stockholm Universities.
Patient 2 is a 6-year-old girl who is treated at the Department of
Pediatric Nephrology of Southwest Texas Methodist Hospital, San
Antonio, TX. She presented in July 2002 at 3 years and 11 months of
age because of hemolytic anemia (hemoglobin 70 g/l), thrombocy-
topenia (29 109/l), reticulocytosis (4.5%; reference area 0.5–1.5%),
and increased lactate dehydrogenase (318 U/l; reference area
155–297 U/l). Results of complement analysis are summarized in
Table 1. The girl developed kidney failure 4 months later, and a renal
biopsy was performed. More than half of the glomeruli (n¼ 30)
showed luminal thrombi. Significant narrowing of the lumina of
arterioli and small arteries was noted. Immunofluorescence showed
focal segmental labeling for IgM and C3 as well as for fibrin. C3
staining was noted in glomerular capillaries and interlobular vessels.
A diagnosis of atypical HUS was made. The child was treated with
plasma exchange. Plasma therapy was discontinued when there were
no signs of disease activity. A blood sample was taken several
months after plasma exchange therapy was terminated. She is
currently treated with peritoneal dialysis. The samples were taken
with the informed consent of the patient’s parents and with the
approval of the Institutional Review Board, University of Texas
Health Science Center at San Antonio.
Normal serum was obtained from 16 healthy adult volunteers
who were not treated with any medications and from 12 pediatric
controls aged 6–16 years (median 9 years). The pediatric controls did
not have a history of renal disease or HUS. In addition, DNA
samples from healthy adults (n¼ 30) were used as controls. Samples
were collected with the approval of the Ethics Committee of Lund
University.
Renal cortical tissue was available from a 55-year-old woman
with renal cancer. Renal tissue from the cancer patient was taken
from a nephrectomized kidney in an area unaffected by cancer.
Renal cortical tissue was also available from a 10-year-old girl
investigated for episodes of macroscopic hematuria in whom the
renal biopsy was deemed normal by light and immunofuorescence
microscopy. Tissue was prepared for paraffin embedding according
to hospital routines.
Bone marrow biopsy was available from a 17-year-old girl who
recovered from aplastic anemia. The marrow was examined by a
hospital pathologist and deemed normal. The control tissue was
taken with the informed consent of the adult patient and the parents
of the children and with the approval of the Ethics Committee of
Lund University. Normal liver and colon tissue were available from
unidentified subjects. The hospital pathologist deemed these tissues
normal.
Genotypic analysis of factor H
DNA was extracted from whole blood using the QIAquick kit (Blood
& Cell Culture DNA Midi Kit 25, Hilden, Germany). Exons and
exon–intron boundaries were amplified, PCR fragments were
purified and automatic sequencing performed as previously
described.6,45 PCR products of exon 13 (CCP 10 of factor H) from
patient 1 and 30 healthy controls were analyzed by single-strand
conformational polymorphism performed with the GenePhor
system (Pharmacia, Uppsala, Sweden). PCR products of exon 23
(CCP 20 of factor H) from patient 2 and 15 healthy controls were
digested with the restriction enzyme MseI (New England BioLabs
Inc., Ipswich, MA, USA).
To determine if both normal and mutated alleles were expressed
in patient 2, RNA was extracted from peripheral blood leukocytes.21
Factor H fragments were amplified from the cDNA product.
Phenotypic analysis of factor H
Rocket immunoelectrophoresis. Factor H levels in sera were
assayed by rocket immunoelectrophoresis.46
Immunoblotting. Factor H was analyzed by immunoblotting
under reducing conditions. Serum samples were diluted 1/50 in
sample buffer and 20 ml per sample were run on a 7.5% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis gel and electro-
blotted according to a method previously described.47 Membranes
were incubated with polyclonal sheep anti-human factor H-IgG
(1:500; The Binding Site, Birmingham, UK) as the primary antibody
followed by donkey anti-sheep IgG/horseradish peroxidase (HRP,
1:5000; ICN Biomedical, Aurora, OH). The signal was detected by
chemiluminescence.
Ouchterlony double immunodiffusion. Factor H antigen was
studied by double immunodiffusion according to Ouchterlony48
comparing patient serum with normal serum.
Immunohistochemistry. Renal and bone marrow biopsies were
formaldehyde-fixed, paraffin-embedded, and prepared as previously
described.49 Samples were tested for the presence of factor H, C3, or
CD14 using goat anti-human factor H-IgG (0.5 mg/ml; Calbiochem,
La Jolla, CA), mouse VIG8 antibody directed to CCPs 19–20 of
factor H (4 mg/ml; a gift from Dr Peter F Zipfel, Hans Knoell
Institute for Natural Products Research, Jena, Germany),50 goat
anti-human C3 (0.5 mg/ml; Sigma, St Louis, MO, USA), or mouse
anti human-CD14 antibodies (for detection of monocytes, 2.3mg/
ml; Dako, Glostrup, Denmark). Normal goat IgG (0.5 mg/ml;
Oncogene, Boston, MA) or mouse IgG1 (DakoCytomation,
Carpinteria, CA) were used as the control antibodies. Sections were
incubated with the primary antibody at 41C overnight followed by
rabbit anti-goat antibody (0.5 mg/ml, Dako; in 2.5% bovine serum
albumin, 0.05 M Tris, pH 7.6, 0.9% NaCl) for 1 h at room
temperature. Detection of staining was achieved using EnVi-
sionTMþ System/HRP rabbit or mouse (DABþ ; DakoCytomation).
Positive samples stained brown.
Functional activity of factor H
Factor H function was tested with regard to its ability to protect
sheep erythrocytes from lysis and binding to endothelial cells.
Hemolysis of sheep erythrocytes. Serum from patient 2 was
compared with serum from 16 adult controls and 12 pediatric
controls, as previously described.26 To evaluate the specificity of the
assay for factor H dysfunction, purified factor H (50 mg/ml;
Calbiochem) was added to patient serum before incubation with
sheep erythrocytes. The assay was not carried out with serum from
patient 1, as the analysis is not meaningful in the presence of
hypocomplementemia.
Factor H binding to endothelial cells detected by immuno-
fluorescence. HUVECs were cultured, fixed, and blocked as
described previously.51 Cells were incubated with sera from either
986 Kidney International (2006) 69, 981–988
o r i g i n a l a r t i c l e F Vaziri-Sani et al.: Phenotypic expression of factor H mutations
one of the patients or two healthy controls (1:100 diluted in
phosphate-buffered saline) followed by goat IgG anti-human factor
H (1.5 mg/ml diluted in phosphate-buffered saline/bovine serum
albumin 3%) for 1 h at 371C. The secondary antibody was rabbit
anti-goat IgG:fluorescein isothiocyanate (1:400; Calbiochem) after
which glass slides were covered with fluorescent mounting medium
(Dako) and examined by fluorescence microscopy (Axiostar plus,
Carl Zeiss, Go¨ttingen, Germany).
Factor H binding to HUVECs detected by flow cytometry.
HUVECs were grown to confluence as described51 and detached by
trypsinization. Factor H binding to cells was analyzed using sera and
antibodies as described above and detected by flow cytometry.32
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